Methicillin-resistant Staphylococcus aureus in trauma and orthopaedic practice

Journal of Bone and Joint Surgery - Series B

Volumn 87, Issue 6, 2005, Pages 749-754

  Giannoudis, P V ^a,b   Parker, J ^a,b   Wilcox, M H ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORHEXIDINE; COTRIMOXAZOLE; METICILLIN; MINOCYCLINE; PENICILLIN BINDING PROTEIN 2A; PSEUDOMONIC ACID; RIFAMPICIN; TRICLOSAN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DEVICE; DRUG POTENTIATION; ECONOMIC ASPECT; GEOGRAPHIC DISTRIBUTION; HAND WASHING; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; ORTHOPEDIC SURGERY; ORTHOPEDICS; PERSONAL HYGIENE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; UNITED KINGDOM;

CROSS INFECTION; HOSPITAL COSTS; HUMANS; METHICILLIN RESISTANCE; ORTHOPEDICS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 20844436782     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.87B6.16292     Document Type: Review

References (83)

1. Jevons MP. Celbenin-resistant staphylococci. BMJ 1961;1:124-5.
2. Health Protection Agency. Mandatory surveillance of surgical site infections in orthopaedic surgery. CDR Weekly 2004;14:21.
3. Abbasi K. Facing the microbial threat. BMJ 1998;317:620.
4. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003;9:1179-86.
5. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13: 50-5.
6. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001;39:3727-32.
7. Vincent JL. Microbial resistance: lessons from the EPIC study. Intensive Care Med 2000;26(Suppl 1):3-8.
8. Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22:406-19.
9. European Antimicrobial Resistance Surveillance System (EARSS). http://www.earss.rivm.nl (accessed 14/04/05).
10. Health Protection Agency. Mandatory bacteraemia surveillance scheme. 2004.
11. De Lucas-Villarrubia JC, Lopez-Franco M, Granizo JJ, De Lucas-Garcia JC, Gomez-Barrena E. Strategy to control methicillin-resistant staphylococcus aureus post-operative infection in orthopaedic surgery. Int Orthop 2004;28:16-20.
12. Tai CC, Nirvani AA, Holmes A, Hughes SP. Methicillin-resistant staphylococcus aureus in orthopaedic surgery. Int Orthop 2004;28:32-5.
13. Health Protection Agency Communicable Disease Surveillance Centre, HCAI & AMR Department. Report: surveillance of surgical site infection in English hospitals, 1997-2002. http:www.hpa.org.uk/infections/topics_az/hai/SSIreport.pdf (accessed 14/04/05).
14. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant staphylococcus aureus. Lancet Infect Dis 2002;2:180-9.
15. Enright MC. The evolution of a resistant pathogen: the case of MRSA. Curr Opin Pharmacol 2003;3:474-9.
16. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant staphylococcus aureus strains. Antimicrob Agents Chemother 2002;46:1147-52.
17. Chambers HF. The changing epidemiology of staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
18. Public Health Laboratory Service. Surveillance report: The socio-economic burden of hospital acquired infection, 1999.
19. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25:425-30.
20. Wilcox MH, Dave J. The cost of hospital-acquired infection and the value of infection control. J Hospital Inf2000; 45:81-4.
21. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-8.
22. Cox RA, Conquest C, Mallaghan C, Marples RR. A major outbreak of methicillin-resistant staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect 1995;29:87-106.
23. Coello R, Glenister H, Fereres J, et al. The cost of infection in surgical patients: a case-control study. J Hosp Infect 1993;25:239-50.
24. Nathwani D. Impact of methicillin-resistant staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother 2003;51(Suppl 2):37-44.
25. Plowman R, Graves N, Griffin MA, et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 2001;47:198-209.
26. Farr BM. Prevention and control of methicillin-resistant staphylococcus aureus infections. Curr Opin Infect Dis 2004;17:317-22.
27. Lucet JC, Chevret S, Durand-Zaleski I, et al. Prevalence and risk factors for carriage of methicillin-resistant staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 2003;163:181-8.
28. Cafferkey MT, Hone R, Keane CT. Sources and outcome for methicillin-resistant staphylococcus aureus bacteraemia. J Hosp Infect 1988;11:136-43.
29. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia dueto methicillin-resistant staphylococcus aureus. Clin Infect Dis 1995;21:1417-23.
30. Maslow JN, Brecher S, Gunn J, et al. Variation and persistence of methicillin-resistant staphylococcus aureus strains among individual patients over extended periods of time. Eur J Clin Microbial Infect Dis 1995;14:282-90.
31. Dancer SJ. Mopping up hospital infection. J Hosp Infect 1999;43:85-100.
32. Stacey A, Burden P, Croton C, Jones E. Contamination of television sets by methicillin-resistant staphylococcus aureus (MRSA). J Hosp Infect 1998;39:243-4.
33. Al-ansari N, Brown N, Foweraker J, Ludlam H. The pre millenium bug?: proceedings of the Pathological Society of Great Britain and Ireland. J Med Microbiol 1999;48:610.
34. Marshall C, Wesselingh S, McDonald M, Spelman D. Control of endemic MRSA: what is the evidence? J Hosp Infect 2004;56:253-68.
35. King S. Provision of alcohol hand rub at the hospital bedside: a case study. J Hosp Infect 2004;56(Suppl 2):10-12.
36. MacDonald A, Dinah F, MacKenzie D, Wilson A. Performance feedback of hand hygiene, using alcohol gel as the skin decontaminant, reduces the number of inpatients newly affected by MRSA and antibiotic costs. J Hosp Infect 2004;56:56-63.
37. Rotter ML. Arguments for alcoholic hand disinfection. J Hosp Infect 2001;48(Suppl A):4-8.
38. Teare L, Cookson B, Stone S. Hand hygiene. BMJ 2001;323:411-12.
39. Gopal Rao G, Jeanes A, Osman M, Aylott C, Green J. Marketing hand hygiene in hospitals: a case study. J Hosp Infect 2002;50:42-7.
40. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HIPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 2002;30:1-413.
41. Infection Control Nurses Association. Hand decontamination guidelines, 2002.
42. Pittet D. Compliance with hand disinfection and its impact on hospital-acquired infections. J Hosp Infect 2001; 48(Suppl A):40-6.
43. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of staphylococcus aureus bacteremia. N Engl J Med 2001;344:11-16.
44. Delafield ME, Sraker D. Antiseptic snuffs. BMJ 1941;1:145-50.
45. Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-6.
46. Wilcox MH, Hall J, Pike H, et al. Use of perioperative mupirocin to prevent methicillin-resistant staphylococcus aureus (MRSA) orthopaedic surgical site infections. J Hosp Infect 2003;54:196-201.
47. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002;35:353-8.
48. Boelaert JR, De Smedt RA, De Baere YA, et al. The influence of calcium mupirocin nasal ointment on the incidence of staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989;4:278-81.
49. Mupirocin Study Group. Nasal mupirocin prevents staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc 1996;7:2403-8.
50. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh H. Elimination of nasal carriage of staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996;17:793-7.
51. Kluytmans JA, Mouton JW, Vanden Bergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of stalphylococcus aureus. Infect Control Hosp Epidemiol 1996;17:780-5.
52. Cimochowski GE, Harostock MD, Brown R, et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001;71:1572-8.
53. Martorell C, Engelman R, Corl A, Brown RB. Surgical site infections in cardiac surgery: an 11-year perspective. Am J Infect Control 2004;32:63-8.
54. Yano M, Doki Y, Inoue M, et al. Preoperative intranasal mupirocin ointment significantly reduces postoperative infection with staphylococcus aureus in patients undergoing upper gastrointestinal surgery. Surg Today 2000;30:16-21.
55. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1412-16.
56. Vasquez JE, Walker ES, Franzus BW, et al. The epidemiology of mupirocin resistance among methicillin-resistant staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000;21:459-64.
57. Revised guidelines for the control of methicillin-resistant staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. J Hosp Infect 1998;39:253-90.
58. Fawley WN, Parnell P, Hall J, Wilcox MH. Surveillance for mupirocin resistance following introduction of routine perioperative prophylaxis with nasal mupirocin [abstract]. Proc 44th Interscience conference on antimicrobial agents and chemotherapy, 2001.
59. Hanssen AD, Osman DR, Nelson CL. Prevention of deep periprosthetic joint infection. Instr Course Lect 1997;46:555-67.
60. Periti P, Mini E, Mosconi G. Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin. J Antimicrob Chemother 1998;41:329-40.
61. No authors listed. Antimicrobial prophylaxis for orthopaedic surgery. Drug Ther Bull 2001;39:43-6.
62. Garner JS. Guideline for isolation precautions in hospitals: part I: evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996;24:24-31.
63. Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant staphylococcus aureus. Am J Epidemiol 1996;143:496-504.
64. Biant LC, Teare EL, Williams WW, Tuite JD. Eradication of methicillin resistant staphylococcus aureus by "ring fencing" of elective orthopaedic beds. BMJ 2004;329: 149-51.
65. Cooper BS, Stone SP, Kibbler CC, et al. Isolation measures in the hospital management of methicillin resistant staphylococcus aureus (MRSA): systematic review of the literature. BMJ 2004;329:533.
66. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362-86.
67. Pittet D. Improving compliance with hand hygiene in hospitals. Infect Control Hosp Epidemiol 2000;21:381-6.
68. Farrington M, Redpath C, Trundle C, Coomber S, Brown NM. Winning the battle but losing the war: methicillin-resistant staphylococcus aureus (MRSA) infection at a teaching hospital. OJM 1998;91:539-48.
69. Kunori T, Cookson B, Roberts JA, Stone S. Kibbler C. Cost-effectiveness of different MRSA screening methods. J Hosp Infect 2002;5:189-200.
70. Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect 2001;48(Suppl A):9-14.
71. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991;35: 1089-92.
72. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;37:209-22.
73. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004;53:345-55.
74. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-8.
75. Moreno F, Crisp C, Jorgensen JH, Patterson JE. Methicillin-resistant staphylococcus aureus as a community organism. Clin Infect Dis 1995;21:1308-12.
76. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004;23:113-19.
77. Wilcox MH. Efficacy of linezol versus comparator therapies in Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):27-35.
78. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
79. Molise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002;50:1017-26.
80. Harwood PJ, Giannoudis PV. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin Drug Saf 2004; 3:405-14.
81. van Saene HK, Weir WI, de la Cal MA, et al. MRSA: time for a more pragmatic approach? J Hosp Infect 2004;56:170-4.
82. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004;56: 321-5.
83. Silvestri L, Milanese M, Oblach L, et al. Enteral vancomycin to control methicillin-resistant staphylococcus aureus outbreak in mechanically ventilated patients. Am J Infect Control 2002;30:391-9.